Psychotropic Drugs and Outcome in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism.

 The influence (if any) of the use of psychotropic drugs on outcome in patients receiving anticoagulant therapy for venous thromboembolism (VTE) has not been consistently evaluated.  We used data from the RIETE (Registro Informatizado Enfermedad TromboEmbólica) database to compare the risk for VTE recurrences, major bleeding, or death during the course of anticoagulant therapy, according to the use of psychotropics at baseline.  Among 49,007 patients with VTE enrolled from February 2009 to September 2019, total 5,230 (11%) were using psychotropics at baseline: antidepressants 3,273 (6.7%), antipsychotics 1,588 (3.2%), and anticholinesterases 369 (0.7%). During the course of anticoagulation, 1,259 patients developed VTE recurrences, 1,231 bled, and 3,988 died (fatal pulmonary embolism 269 and fatal bleeding 187). On multivariable analysis, patients using psychotropics at baseline had a similar risk for VTE recurrences (adjusted hazard ratio [HR]: 0.81; 95% confidence interval [CI]: 0.58-1.12), a nonsignificantly higher risk for major bleeding (adjusted HR: 1.15; 95% CI: 0.97-1.35), and a higher risk for intracranial bleeding (adjusted HR: 1.83; 95% CI: 1.32-2.53) or death (adjusted HR: 1.44; 95% CI: 1.32-1.57) compared with those not using psychotropics. When separately analyzed, the highest risk for intracranial bleeding was found in patients using antidepressants (adjusted HR: 1.60; 95% CI: 1.08-2.37) or antipsychotics (adjusted HR: 2.02; 95% CI: 1.17-3.49) but not in those on anticholinesterases (adjusted HR: 1.69; 95% CI: 0.62-4.60).  During the course anticoagulation for VTE, patients using psychotropics at baseline were at increased risk for intracranial bleeding.

Marchena PJ ，Tzoran I ，Brenner B ，Martín M ，Malý R ，Bura-Riviere A ，Valle R ，Hernández-Blasco L ，López-Sáez JB ，Monreal M ，RIETE Investigators ... -  《-》

Statin and all-cause mortality in patients receiving anticoagulant therapy for venous thromboembolism. Data from the RIETE registry.

The clinical outcomes during the course of anticoagulation in patients with venous thromboembolism (VTE) using statins remain controversial. We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) registry to compare the risk for VTE recurrences, major bleeding or death during anticoagulation, according to the use of statins at baseline. We used propensity score-matching (PSM) to adjust for confounding variables. From February 2009 to January 2018, 32,062 VTE patients were included. Of these, 7,085 (22%) were using statins. Statin users were 10 years older (73±11 vs. 63±19 years, respectively) and more likely to have comorbidities or to be using antiplatelets or corticosteroids at baseline than non-users. During the course of anticoagulation (median, 177 days), 694 patients developed VTE recurrences, 848 bled and 3,169 died (fatal pulmonary embolism 176, fatal bleeding 121). Statin users had a similar rate of VTE recurrences (hazard ratio [HR]: 0.98; 95%CI: 0.82-1.17), a higher rate of major bleeding (HR: 1.29; 95%CI: 1.11-1.50) and a similar mortality rate (HR: 1.01; 95%CI: 0.93-1.10) than non-users. On PSM analysis, statin users had a significantly lower risk for death (HR: 0.62; 95%CI: 0.48-0.79) and a similar risk for VTE recurrences (HR: 0.98; 95%CI: 0.61-1.57) or major bleeding (HR: 0.85; 95%CI: 0.59-1.21) than non-users. During anticoagulation for VTE, patients using statins at baseline had a lower risk to die than non-users.

Siniscalchi C ，Quintavalla R ，Rocci A ，Riera-Mestre A ，Trujillo-Santos J ，Suriñach JM ，Jara-Palomares L ，Bikdeli B ，Moustafa F ，Monreal M ，RIETE Investigators ... -  《-》

Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism.

Kuperman A ，López-Reyes R ，Bosco LJ ，Lorenzo A ，José B ，Farge Bancel D ，Alfonso M ，Lumbierres M ，Stemer G ，Monreal Bosch M ，Braester A ，RIETE Investigators ... -  《-》

Venous Thromboembolism in Patients With Autoimmune Disorders: Findings From the RIETE Registry.

Sada PR ，López-Núñez JJ ，Samperiz A ，Soto MJ ，Pedrajas JM ，Porras JA ，Peris ML ，Olivé A ，Debourdeau P ，Pace F ，Monreal M ，RIETE Investigators ... -  《-》

Sex differences in patients receiving anticoagulant therapy for venous thromboembolism.

Blanco-Molina A ，Enea I ，Gadelha T ，Tufano A ，Bura-Riviere A ，Di Micco P ，Bounameaux H ，González J ，Villalta J ，Monreal M ，RIETE Investigators ... -  《-》